---
schema_version: "secwatch.filing_event.v1"
accession: "0000939767-23-000072"
form_type: "8-K"
ticker: "EXEL"
cik: "0000939767"
company_name: "EXELIXIS, INC."
filed_at: "2023-07-24T23:59:59+00:00"
generated_at: "2026-06-13T04:43:32.851341+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Exelixis settles patent litigation with Teva; generic CABOMETYX license begins Jan 1, 2031

## Summary
- Settlement and License Agreement with Teva resolves patent litigation over generic CABOMETYX (cabozantinib).
- Teva may market generic cabozantinib from January 1, 2031, if FDA approved and subject to standard conditions.
- All pending Hatch-Waxman litigation between Exelixis and Teva in Delaware will be dismissed.
- Agreement is confidential and subject to review by FTC and DOJ.
- Expected to protect CABOMETYX exclusivity in the U.S. until at least January 1, 2031.

## SEC filing metadata
- accession: 0000939767-23-000072
- form_type: 8-K
- ticker: EXEL
- cik: 0000939767
- company_name: EXELIXIS, INC.
- filed_at: 2023-07-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/939767/000093976723000072/0000939767-23-000072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/939767/000093976723000072/exel-20230718.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000939767-23-000072
- JSON: https://secwatch.observer/filing/0000939767-23-000072.json
- Plain text: https://secwatch.observer/filing/0000939767-23-000072.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.